| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Whitehawk Therapeutics, Inc.$3.84
-0.05 (-1.29%)
D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
222.04 M
EPS
-1.67
P/E Ratio
-
Value Trade
719.75 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
-
R&D Expenses
17.23 M
Operating CF
-22.21 M
Total Assets
127.23 M
Total Liabilities
11.06 M
Equity
116.17 M
D/E Ratio
12,345
-10.38 %
Week
7.42 %
1 Month
47.7 %
3 Month
124.5 %
6 Month
-99 %
5 Year
-99.67 %
All Time
Cash Data
Cash Position
123.04 M
Monthly Burn
7.40 M
Runway
14.2 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
66.97 K
52 Week Range
1.57 - 5.50
% held by Insiders
39.35 %
% held by Institutions
53.46 %
Enterprise Value
99.00 M
Total Shares
49.48 M
Short %
10.59 %
Float Shares
26.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Whitehawk Therapeutics, Inc.
266Total events
8Upcoming
68Tier-1 (high impact)
2017 – 2028Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2IND Submission
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
●Trial InitiationHWK-206Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | HWK-206 | IND Submission | IND | — | – | – | – |
2026-06-30 | HWK-206 | IND Submission | IND | — | – | – | – |
2026-06-30 | HWK-206 | IND Submission | IND | — | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $7M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 26%
Micro Cap (rank 677 of 913)
Percentile RankWhitehawk Therapeutics, Inc. faces pipeline headwinds (26/100), with $75M risk-adjusted pipeline value, led by HWK-016, MUCIN-16-targeted ADC in PROC (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HWK-016, MUCIN-16-targeted ADC Small molecule | PROC | Phase 1 | NCT07470853 | 5% | $71M | RECRUITING | 265 | STALLED | C (43) | Feb 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nab-sirolimus | solid tumors with TSC1 or TSC2 inactivating alterations | — | 2023-12-14 | 19 patients received 1 post baseline scan and were evaluable for efficacy; all 18 patients received 1 post baseline scan and were evaluable for efficacy. Read More | Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigator Read More | |
nab-sirolimus | solid tumors with TSC1 or TSC2 inactivating alterations | — | 2023-12-14 | 19 patients received 1 post baseline scan and were evaluable for efficacy; all 18 patients received 1 post baseline scan and were evaluable for efficacy. Read More | Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigator Read More | |
nab-sirolimus | solid tumors with TSC1 or TSC2 inactivating alterations | — | 2023-12-14 | 19 patients received 1 post baseline scan and were evaluable for efficacy; all 18 patients received 1 post baseline scan and were evaluable for efficacy. Read More | Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigator Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WHWK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
WHWK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
WHWKRiassunto: Biocytogen e Whitehawk Therapeutics sottoscrivono una collaborazione globale orientata allo sviluppo di ADC basati su anticorpi bispecifici
Biocytogen and Whitehawk Therapeutics have signed a global collaboration agreement focused on the development of bispecific antibody-based ADCs. This partnership aims to leverage both companies' expertise in advancing innovative therapies. Further details on the specific objectives or timelines of the collaboration were not disclosed.
Read more →WHWKSamenvatting: Biocytogen en Whitehawk Therapeutics gaan een globale samenwerking aan voor de ontwikkeling van bispecifieke antilichaam-geneesmiddelconjugaten
Biocytogen and Whitehawk Therapeutics have announced a global collaboration to develop bispecific antibody-drug conjugates. The partnership aims to leverage both companies' expertise in biopharmaceuticals to enhance therapeutic options. Further details on the specific projects or timelines were not provided in the announcement.
Read more →WHWKResumen: Biocytogen y Whitehawk Therapeutics firman un acuerdo de colaboración internacional para el desarrollo de anticuerpos bispecíficos ADC
Biocytogen and Whitehawk Therapeutics have entered into an international collaboration agreement focused on the development of bispecific antibody-drug conjugates (ADCs). This partnership aims to leverage the strengths of both companies in advancing innovative therapeutic solutions. Further details about the specific terms of the agreement and its implications for future projects were not disclosed.
Read more →WHWKBiocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC)
Biocytogen and Whitehawk Therapeutics have announced a global collaboration to develop bispecific antibody-drug conjugates (ADCs). This partnership aims to leverage each company's expertise in biopharmaceutical development to enhance therapeutic options. Further details regarding the specific goals or timelines of the collaboration were not disclosed.
Read more →WHWKBiocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
Biocytogen and Whitehawk Therapeutics have announced a global collaboration aimed at developing bispecific antibody antibody-drug conjugates (ADCs). This partnership is expected to leverage both companies' expertise in biopharmaceuticals. Further details on the specific goals and timelines of the collaboration have not been disclosed.
Read more →WHWKWhitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics presented a real-world analysis at ASCO 2026, highlighting SEZ6 as a significant target for small cell lung cancer (SCLC) and other neuroendocrine tumors. The analysis indicates that SEZ6 is highly expressed in these cancers, supporting the development of the SEZ6-directed ADC, HWK-206, with an IND submission expected in mid-2026. The findings suggest promising therapeutic implications for patients.
Read more →WHWKWhitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
Whitehawk Therapeutics, a clinical-stage oncology company, announced that its President and CEO, Dave Lennon, will present at the Jefferies 2026 Global Healthcare Conference on June 4. The presentation will focus on the company's innovative antibody drug conjugate (ADC) treatments. A live webcast of the event will be available for 30 days post-presentation.
Read more →WHWKWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Whitehawk Therapeutics has entered an option agreement with Hangzhou DAC to develop up to five new antibody-drug conjugate (ADC) programs using the CPT113 linker-payload technology. This agreement aims to enhance their existing ADC pipeline, which includes ongoing Phase 1 trials for HWK-007 and HWK-016. The company plans to submit Investigational New Drug applications for these new programs within the next 12-24 months.
Read more →WHWKWhitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics has entered an option agreement with Hangzhou DAC to develop up to five new antibody-drug conjugate (ADC) programs using the CPT113 linker-payload technology. This agreement is expected to enhance their pipeline, with multiple Investigational New Drug applications anticipated in the next 12-24 months. Current Phase 1 trials for HWK-007 and HWK-016 are ongoing, with data expected in 2027.
Read more →WHWKWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
Whitehawk Therapeutics will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. CEO Dave Lennon will engage in a virtual fireside chat, discussing advancements in antibody drug conjugate cancer treatments. The event will be accessible via a live webcast and available for replay for 30 days.
Read more →WHWK▼ -7.8%on this newsshared move
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Whitehawk Therapeutics will participate in the 2026 Stifel Virtual Targeted Oncology Forum, with CEO Dave Lennon leading a fireside chat on May 19, 2026. The event will be accessible via a live webcast and available for replay for 30 days. Whitehawk focuses on developing advanced antibody drug conjugates to enhance cancer treatment.
Read more →WHWK▲ +25.8%on this newsshared move
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing MORRISTOWN, NJ
Whitehawk Therapeutics announced a successful private placement equity financing, raising approximately $87.5 million. The financing involves the sale of common stock and pre-funded warrants, with a closing date anticipated on May 14, 2026. Funds will be allocated towards working capital and advancing the company's antibody drug conjugate pipeline, extending its cash runway into the second half of 2028. Participation from existing investors underscores their confidence in the company's oncology therapeutic development efforts.
Read more →WHWK▲ +25.8%on this newsshared move
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
Whitehawk Therapeutics has announced a private placement equity financing expected to generate approximately $87.5 million. The funds will be used for working capital and advancing its antibody drug conjugate pipeline. The financing is set to close on May 14, 2026, pending customary conditions. Existing investors are participating, reflecting confidence in the company's future.
Read more →WHWK▼ -5.1%on this news
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics, Inc. reported its financial results for Q1 2026, highlighting ongoing Phase 1 trials for its ADC assets, HWK-007 and HWK-016. The company maintains a strong cash position of $123 million, which is expected to support operations into 2028. An IND submission for HWK-206 is on track for mid-2026, with initial data anticipated in 1H 2027. However, the company reported increased operating losses and acknowledged uncertainties related to clinical development risks.
Read more →WHWK▼ -5.1%on this news
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cas
Whitehawk Therapeutics has reported its financial results for Q1 2026, revealing ongoing Phase 1 trials for its drug candidates HWK-007 and HWK-016, and plans to submit an IND application for HWK-206. As of March 31, 2026, the company holds $123 million in cash, which is expected to support operations into 2028. While the net loss has increased compared to the previous year, positive data on its ADC portfolio was presented, highlighting the potential benefits for patients with hard-to-treat cancers. The company anticipates initial data from these trials in the first half of 2027.
Read more →WHWKWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Whitehawk Therapeutics presented new preclinical data on its ADC portfolio at the AACR Annual Meeting 2026. The data highlighted significant tumor regressions at low doses and favorable tolerability across various cancer models. Ongoing Phase 1 trials for HWK-007 and HWK-016 are progressing, with an IND submission for HWK-206 expected in mid-2026.
Read more →WHWKWhitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics presented promising preclinical data for its ADC portfolio at AACR 2026. The data showed significant tumor regressions and favorable tolerability across various cancer models. Ongoing Phase 1 trials for HWK-007 and HWK-016 are progressing, with an IND submission for HWK-206 expected in mid-2026. The results support the potential of Whitehawk's proprietary technologies in developing advanced cancer therapies.
Read more →WHWKWhitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
Whitehawk Therapeutics, Inc. will participate in the Jones Trading Post-AACR Fireside Chat Series on April 23, 2026. CEO Dave Lennon, PhD, will discuss the company's advancements in antibody drug conjugate cancer treatments. The event will be accessible via a live webcast and available for replay for 30 days.
Read more →WHWKWhitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics presented findings at the SGO 2026 Annual Meeting, highlighting MUC16 as a significant target for gynecologic cancers. MUC16 demonstrates stable and high expression in ovarian and endometrial cancers, supporting the rationale for their investigational ADC, HWK-016, for patients with advanced disease. Initial clinical data for HWK-016 is anticipated in mid-2027, with real-world data reinforcing its potential as an effective treatment option. However, there are notable risks and uncertainties associated with its clinical development and potential side effects during trials.
Read more →WHWKWhitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
Whitehawk Therapeutics will showcase its next-generation ADC portfolio at the AACR Annual Meeting 2026. The company will present three preclinical abstracts, including an oral presentation and two posters, highlighting the efficacy and safety of its ADC programs HWK-007, HWK-016, and HWK-206. These programs aim to improve cancer treatment outcomes through optimized design features.
Read more →WHWKWhitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics reported its financial results for Q4 and full-year 2025, highlighting active recruitment for Phase 1 trials of two antibody-drug conjugates (ADCs). The company has a robust cash balance of $145.7 million, expected to sustain operations through 2028. Plans for an IND submission for HWK-206 are on track for mid-2026, with clinical data anticipated to have a significant impact on patient care.
Read more →WHWKThree months ended December 31, Twelve months ended
Whitehawk Therapeutics has reported its financial results for the fourth quarter and full year of 2025, highlighting progress in its clinical trials and financial health. The company is actively recruiting for two Phase 1 studies targeting HWK-007 and HWK-016, with the planned IND submission for HWK-206 also on track. Whitehawk's cash balance stands at $145.7 million, sufficient to fund operations into 2028, while recent data presentation emphasizes the promise of PTK7 as a relevant target across solid tumors. Despite a net loss increase in Q4, the overall financial situation shows marked improvement over the previous year.
Read more →WHWKWhitehawk Therapeutics to Participate in Upcoming Investor Conferences
Whitehawk Therapeutics, Inc. announced its participation in upcoming investor conferences, showcasing its commitment to oncology therapeutics. The company focuses on advanced antibody drug conjugate (ADC) technologies to improve cancer treatment outcomes. Live webcasts of the presentations will be available for replay for 30 days post-event.
Read more →WHWKWhitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Whitehawk Therapeutics, a clinical-stage oncology therapeutics company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Dave Lennon will discuss the company's innovative antibody drug conjugate (ADC) cancer treatments. The presentation will be accessible via a live webcast and available for replay for 30 days.
Read more →WHWKWhitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026. CEO Dave Lennon will discuss the company's innovative antibody drug conjugate (ADC) cancer treatments. The presentation will be accessible via a live webcast and available for replay for 30 days.
Read more →WHWKWhitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...
Whitehawk Therapeutics has successfully received FDA clearance for the Investigational New Drug (IND) application for its HWK-007, a PTK7-targeted antibody-drug conjugate. The company is actively recruiting for a Phase 1 trial targeting lung, ovarian, and endometrial cancers. Additionally, an IND for HWK-016, targeting MUC16, has been submitted, with recruitment for its Phase 1 trial expected to commence shortly. Initial clinical data from both studies is anticipated in early 2027, exemplifying the company's commitment to innovative cancer therapies.
Read more →WHWKWhitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Whitehawk Therapeutics has appointed Dr. Margaret Dugan as Chief Medical Officer. With over 30 years of experience in oncology drug development, Dr. Dugan is expected to strengthen the company's clinical strategies as it advances its antibody drug conjugate (ADC) portfolio. Her prior roles include leadership positions at Novartis and Dracen Pharmaceuticals, where she contributed to significant regulatory approvals.
Read more →WHWK▲ +7%on this newsshared move
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Whitehawk Therapeutics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Dave Lennon will lead a fireside discussion, which will also be available via live webcast. The company focuses on advanced antibody drug conjugate therapies for challenging cancers.
Read more →WHWKWhitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
Whitehawk Therapeutics, an oncology therapeutics company, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. CEO Dave Lennon will discuss the company's innovative antibody drug conjugate (ADC) cancer treatments. A live webcast will be available for those unable to attend the event.
Read more →WHWK▼ -6.7%on this newsshared move
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics reported its third quarter 2025 financial results, highlighting a focus on executing its plans for IND filings for HWK-007 and HWK-016. The company emphasized its financial discipline and the promising data regarding PTK7 as a tumor marker. However, it also noted increased operational losses and potential risks in clinical development.
Read more →WHWK▼ -6.7%on this newsshared move
WHITEHAWK THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (In thousands, except share data and earnings per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended
Whitehawk Therapeutics, Inc. reported its financial results for the third quarter of 2025, noting a net loss of $17.7 million. The company is progressing towards IND filings for its ADC candidates HWK-007 and HWK-016 by the end of the year. In addition, recent data confirms the therapeutic potential of PTK7 as a target for cancer treatment. Despite these advances, the increased net loss and significant operational expenses raise concerns about the company’s financial stability.
Read more →WHWKWhitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
Whitehawk Therapeutics presented a real-world analysis confirming Protein Tyrosine Kinase 7 (PTK7) as a significant target across various solid tumors at the AACR-NCI-EORTC conference. The analysis revealed that PTK7 is expressed in approximately 70% of tumors, supporting the development of HWK-007, a PTK7-directed antibody-drug conjugate. The findings highlight PTK7's potential as a clinically relevant target for cancer therapies.
Read more →WHWKWHITEHAWK THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (In thousands, except share data and earnings per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended
Whitehawk Therapeutics, Inc. reported its second quarter financial results for 2025, highlighting advancements in its antibody-drug conjugate (ADC) portfolio. The company plans to file INDs for two programs by the end of 2025, with a third program to follow in mid-2026. Despite a cash balance of $177.2 million that supports operations into 2028, the company reported a substantial net loss of $52.6 million in the second quarter, up from $14.6 million in the previous year, amid uncertainties in clinical development.
Read more →WHWKWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to...
Whitehawk Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting advancements in its antibody-drug conjugate (ADC) portfolio. The company is on track to file INDs for two programs by the end of 2025, with another expected in mid-2026. Despite a significant net loss of $52.6 million this quarter, Whitehawk's cash reserves are viewed as sufficient to support ongoing clinical developments. The company emphasizes the need for caution regarding potential risks tied to the clinical testing of its assets.
Read more →WHWKWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Whitehawk Therapeutics, Inc. announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025. The company focuses on developing advanced antibody-drug conjugates (ADCs) to enhance cancer treatment efficacy. This event highlights Whitehawk's ongoing efforts to innovate in oncology therapeutics.
Read more →WHWKWhitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
Whitehawk Therapeutics, Inc. announced its participation in the H.C. Wainwright "HCW@Home" series scheduled for June 26, 2025. The event will feature CEO Dave Lennon and CSO David Dornan discussing the company's advancements in oncology therapeutics. A live webcast will be available, with a replay accessible for 30 days post-event.
Read more →WHWKWhitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to...
Whitehawk Therapeutics, Inc. will present at the Jefferies 2025 Global Healthcare Conference from June 3-5, 2025, in New York City. CEO Dave Lennon will provide an overview of the company's activities on June 4. The event will include a live webcast accessible for those interested in the company's advanced cancer treatments which utilize innovative technology. This presentation highlights Whitehawk's commitment to enhancing oncology therapeutics.
Read more →WHWKWhitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to...
Whitehawk Therapeutics, Inc. announced that its president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 28, 2025. The summit will provide insights for the forthcoming ASCO & EHA conferences. A live webcast of the discussion will be available on the company's investor relations website and can be replayed for about 30 days after the event. This appearance highlights Whitehawk's commitment to advancing oncology therapeutics.
Read more →WHWKWhitehawk Reports First Quarter 2025 Financial Results and Recent Highlights
Whitehawk Therapeutics reported its first quarter 2025 financial results, showcasing significant advancements in its ADC portfolio aimed at treating difficult cancers. The company is on track to file its first IND by Q4 2025 and aims to bring all three assets to IND by mid-2026. Financially, Whitehawk achieved a notable net income of $73 million, reflecting a substantial improvement from the previous year.
Read more →WHWKWhitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to...
Whitehawk Therapeutics, Inc. announced the successful closure of the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $100 million. This divestiture is part of a strategic transformation plan initiated in December 2024. The proceeds will be utilized to advance Whitehawk's antibody drug conjugate portfolio and support general operations, ensuring funding through 2028. This transaction positions Whitehawk to enhance its capabilities in developing novel cancer treatments.
Read more →WHWKAadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strate
Whitehawk Therapeutics, formerly known as Aadi Bioscience, has officially relaunched and rebranded to focus on antibody-drug conjugates (ADCs). The strategic transition is supported by a portfolio of three ADC assets developed in collaboration with WuXi Biologics. Financial resources are projected to sustain operations through to 2028, enabling essential clinical data collection. The company aims to bring all three assets to IND status within the next 15 months. Despite potential challenges in clinical development and unexpected reactions during trials, the management expresses confidence in overcoming previous ADC limitations.
Read more →WHWKAadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies ...
Whitehawk Therapeutics, formerly Aadi Bioscience, has rebranded to focus on advancing its portfolio of antibody drug conjugates (ADCs). The company is expected to have sufficient funding to support operations until 2028, with plans to bring three ADC assets to IND within the next 15 months. Despite a reported net loss, the strategic shift aims to enhance treatment options for difficult cancers.
Read more →WHWKAadi Bioscience Announces Closing of $100 Million PIPE Financing MORRISTOWN, NJ
Aadi Bioscience has successfully closed a private placement financing of approximately $100 million, led by Ally Bridge Group and involving several new and existing investors. The financing included the sale of common stock and pre-funded warrants to support the company's oncology programs. The funds will be directed towards funding commitments under a license agreement and general operational costs. This successful capital raise is expected to extend Aadi's operational runway into 2028.
Read more →WHWKAadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO and $100 Million PIPE Financing Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collab
Aadi Bioscience has entered into an exclusive license agreement for a three-asset portfolio of preclinical antibody-drug conjugates (ADCs) and announced the sale of its FYARRO product and associated infrastructure for $100 million. The company also completed a PIPE financing round, raising an additional $100 million to fund operations projected into late 2028. Baiteng Zhao has been appointed to the board, bringing valuable ADC expertise to guide the company's strategies. Together, these developments position Aadi for potential growth and innovation in cancer therapeutics.
Read more →WHWKAadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update FYARRO sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth Aadi continues to focus on FYARRO
Aadi Bioscience reported its third quarter 2024 financial results, highlighting FYARRO sales of $7.2 million, marking a 21% increase year-over-year. The company noted significant demand and a strong reorder rate of nearly 90% for FYARRO. Aadi is also conducting a strategic review to enhance shareholder value. However, despite this growth, the company reported a net loss and high operating expenses compared to the prior year.
Read more →WHWKAadi Bioscience Provides PRECISION1 Trial and Corporate Updates PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO commer
Aadi Bioscience has announced that it will halt its PRECISION1 trial after an independent analysis indicated it is unlikely to meet regulatory approval thresholds. The company plans to shift its focus to its commercial product, FYARRO, which generated $6.2M in sales last quarter, and will conduct a strategic review to enhance shareholder value. Due to cash preservation measures, Aadi is reducing its R&D workforce by 80% and pausing new patient enrollment in two ongoing Phase 2 trials.
Read more →WHWKAadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update FYARRO sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fu
Aadi Bioscience reported its second quarter 2024 financial results, revealing FYARRO sales of $6.2 million, a 15% increase from Q1 2024. The company highlighted strong demand from oncology centers, with many accounts ordering repeatedly. Aadi is set to provide an interim analysis of its clinical trial PRECISION1 in Q3 2024, which explores nab-sirolimus for various solid tumors. However, the company also reported a net loss of $14.6 million, alongside a decrease in cash reserves, raising concerns about financial stability.
Read more →WHWKAadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial two-thirds interim analysis planned for Q3 2024 FYARRO sales of $
Aadi Bioscience announced its financial results for Q1 2024, highlighting full enrollment in the PRECISION1 trial and ongoing Phase 2 trials. The company reported FYARRO sales of $5.4 million, which decreased from the previous year primarily due to shifting distributor ordering patterns and fewer patient initiations. Despite these sales challenges, Aadi remains optimistic about growth in Q2. The company's cash reserves are projected to fund operations through Q4 2025, and it plans to provide key trial data in the coming months.
Read more →WHWKAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growt
Aadi Bioscience reported financial results for Q4 and full-year 2023, showcasing substantial growth in FYARRO sales. The company achieved a 21% increase in quarterly sales and a remarkable 60% growth for the full year. Aadi is advancing its PRECISION1 trial and has begun Phase 2 trials for endometrial cancer and neuroendocrine tumors. However, the company also reported increased net losses compared to the previous year.
Read more →WHWKAadi Bioscience Reports Interim Results from PRECISION1 Trial of nab -Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Interim results from investigator
Aadi Bioscience has reported promising interim results from its PRECISION1 trial, demonstrating anti-tumor activity of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. The results are based on a planned analysis of the first 40 patients who have shown sustained tumor reductions despite previous treatments. The trial currently includes 80 participants, with further analysis anticipated in 2024 and a final data readout in early 2025. The safety profile of nab-sirolimus remains consistent with expectations, showing no new adverse events.
Read more →WHWKAadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of
Aadi Bioscience announced its third-quarter 2023 financial results, showing a significant increase in FYARRO sales by 40% year-over-year, amounting to $6.0 million. The company is progressing with the PRECISION1 trial, which is set for an early interim analysis presentation by mid-December 2023. Additionally, Aadi has initiated new Phase 2 studies in endometrial and neuroendocrine tumors. The overall financial position remains stable with sufficient funding projected to extend into 2025.
Read more →WHWKAadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commerciali
Aadi Bioscience has appointed Dave Lennon, Ph.D. as President and CEO, highlighting his two decades of pharmaceutical expertise, particularly in oncology. This leadership change aims to leverage mTOR technology to boost the company's growth trajectory as it prepares for interim analysis on its precision oncology trials. Lennon’s background includes significant roles at Novartis, where he led the approval and launch of Zolgensma, reinforcing Aadi's commitment to developing novel cancer therapies. The company looks forward to new trials for FYARRO aimed at helping patients with specific cancer alterations.
Read more →WHWKAadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update Continued growth in total revenue on FYARRO with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40
Aadi Bioscience has reported a financial uplift in its second quarter of 2023, with FYARRO sales reaching $6.2 million, an increase from previous quarters. The company is progressing well with the PRECISION1 trial, which is set for an interim analysis by year's end, and is actively expanding its pipeline to include trials for Endometrial Cancer and Neuroendocrine Tumors. The firm aims to initiate these new studies by the fourth quarter of 2023, while managing a net loss of $18 million for the quarter.
Read more →WHWKAadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial Total 1Q 2023 revenue on FYARRO sales of $5.9 million PRECISION 1 tumo
Aadi Bioscience reported strong financial results for Q1 2023, with FYARRO sales reaching $5.9 million, marking a 12% increase from the previous quarter. The company provided an update on the PRECISION 1 trial, noting balanced enrollment across tumor types and a planned interim analysis by the end of 2023. However, the company also highlighted a growing net loss of $15.2 million and acknowledged the need for careful monitoring of the trial's efficacy.
Read more →WHWKAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update Total revenue on FYARRO sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected i
Aadi Bioscience has announced its financial results for the fourth quarter and full-year 2022, reporting total revenue of $15.2 million from FYARRO sales. The company's CFO highlighted significant achievements including a $72.5 million financing that extends its cash runway until 2025. Looking forward, Aadi anticipates releasing preliminary data from its PRECISION 1 trial in the second quarter of 2023, furthering its efforts to advance precision therapies in oncology.
Read more →WHWKAadi Bioscience Announces Leadership Transition
Aadi Bioscience has announced a leadership transition following the resignation of CEO Brendan Delaney for personal reasons. Scott Giacobello, the company's Chief Financial Officer, has been appointed as the Interim CEO while the Board of Directors initiates a search for a permanent replacement. The company is continuing its focus on developing FYARRO, a treatment for certain cancer patients, supported by a robust leadership team.
Read more →WHWKAadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update Completed $72.5 million PIPE financing extending cash runway into 2025 PRECISION 1 trial on-track with preliminary d
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update Completed $72.5 million PIPE financing extending cash runway into 2025 PRECISION 1 trial on-track with preliminary data expected in the first half of 2023 24% revenue growth
Read more →WHWKAadi Bioscience Announces $72.5 Million Private Placement Equity Financing
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing LOS ANGELES, Sept. 22, 2022 /PRNewswire/ Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations
Read more →WHWKAadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update FYARRO (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 PRECISION 1 Phase 2 tu
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update FYARRO (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enroll
Read more →WHWKAadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update FYARRO net product sales of $2.3 million in partial first quarter Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update LOS ANGELES, CA, May 12, 2022 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined can
Read more →WHWKAadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update -FYARRO approved
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update -FYARRO approved November 22, 2021 and launched February 23, 2022- -FYARRO added to NCCN Guidelines as the only preferred therapy to treat -PRECISION 1 tumor agnostic study for TSC1
Read more →WHWKAadi Bioscience Announces FDA Approval of its First Product FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) FYARRO is the first and only approve
Aadi Bioscience Announces FDA Approval of its First Product FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) LOS ANGELES, November 23, 2021 Aadi Bioscience, Inc. ( Aadi ) (Nasdaq: AADI), a biopharmaceutic
Read more →WHWKAadi Reports Third Quarter 2021 Financial Results and Provides Business Update FYARRO under review with FDA with a
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update November 10, 2021 Aadi Bioscience, Inc. ( Aadi ) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pa
Read more →WHWKAadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer LOS ANGELES, November 1, 2021 Aadi Bioscience, Inc. ( Aadi ) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR
Read more →WHWKAadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer LOS ANGELES, Sept. 20, 2021 Aadi Bioscience, Inc. ( Aadi ) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pat
Read more →WHWKAadi Bioscience Appoints Emma Reeve to its Board of Directors
Aadi Bioscience Appoints Emma Reeve to its Board of Directors LOS ANGELES, Sept. 13, 2021 Aadi Bioscience, Inc. ( Aadi ) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway g
Read more →WHWKCorporate Overview August 2021 NASDAQ: AADI www.aadibio.com Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation
Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1Exhibit 99.1 Corporate Overview August 2021 NASDAQ: AADI www.aadibio.com Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA 1 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this pr
Read more →WHWKAerpio Reports Second Quarter 2021 Financial Results and Provides Business Update Ended second quarter 2021 with $36.8 million in cash and cash equivalents On
Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update August 11, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2021 and provided
Read more →WHWKAadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO for the Treatment of Advanced Malignant PEComa FDA grants Priority Review and sets PDUFA target action date of
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO for the Treatment of Advanced Malignant PEComa LOS ANGELES, Ca. July 26, 2021 - Aadi Bioscience, Inc. ( Aadi ), a privately-held, clinical-stage biopharmaceutical company focusi
Read more →WHWKAerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting Ohio, June 4, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO) announced that Aadi Bioscience, Inc. ( Aadi ), a privately-held biopharmaceutical company focusing on precisi
Read more →WHWKAerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting CINCINNATI, Ohio, May 19, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO) announced that Aadi Bioscience ( Aadi ), a privately-held biopharmaceutical company focusing on precisio
Read more →WHWKAerpio Reports First Quarter 2021 Financial Results and Provides Business Update Ended first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to
Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update CINCINNATI, Ohio, May 17, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2, today reported financial resu
Read more →WHWKAerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience s late-stage pipeline for genetically-defined cancers w
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement CINCINNATI, Ohio and PACIFIC PALISADES, California, May 17, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate
Read more →WHWKAerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Ended fourth quarter 2020 with $42.6 million in cash and cash equivalents Aerpio is currently evaluating a range of strategi
Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update CINCINNATI, Ohio, March 11, 2021 Aerpio Pharmaceuticals, Inc. ( Aerpio or the Company ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie
Read more →WHWKQuantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical s Razuprotafib in I-SPY COVID Trial
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical s Razuprotafib in I-SPY COVID Trial March 5, 2021, San Francisco, CA and Cincinnati, OH Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with
Read more →WHWKAerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial CINCINNATI
Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial CINCINNATI, January 5, 2021, Aerpio Pharmaceuticals, Inc. ( Aerpio or the Company ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2,
Read more →WHWKAerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanaprost control group. Patient enr
Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanaprost control group. Patient enrollment and dosing continues in both COVID-19 clinical t
Read more →WHWKAerpio Reports Third Quarter 2020 Financial Results and Provides Business Update Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly i
Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Today, November 10, 2020 at 8:30 a.m. EST CINCINNATI, Ohio, November 10, 2020 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company focused on develop
Read more →WHWKAerpio Reports Second Quarter 2020 Financial Results and Provides Business Update Initiated a Phase 2 Open Angle Glaucoma Trial; Recruiting Ahead of Schedule Announced Partnership with I-SPY to Participate in a Clinical
Aerpio Reports Second Quarter 2020 Financial Results and Provides Conference Call Today, August 12, 2020 at 8:30 a.m. EST CINCINNATI, Ohio, August 12, 2020 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that
Read more →WHWKAerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19. CINCINNATI
Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19. CINCINNATI, August 4, 2020 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARP
Read more →WHWKAerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial CINCINNATI
Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib CINCINNATI June 24, 2020 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, an
Read more →WHWKAerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 P
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients SAN FRANCISCO, CINCINNATI, DATE (May 27, 2020) A
Read more →WHWKAerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924). Aerpio Received an Immediate Payment of $15 million. CINCINNATI (BUSINESS WIR
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924). Aerpio Received an Immediate Payment of $15 million. CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO)
Read more →WHWKAerpio Reports First Quarter 2020 Financial Results and Provides Business Update Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start
Aerpio Reports First Quarter 2020 Financial Results and Provides Razuprotafib (formerly known as AKB-9778) Phase 2 Open Angle Glaucoma Trial on Track for Third Quarter Start CINCINNATI, Ohio, May 7, 2020 Aerpio Pharmaceuticals, Inc. ( Aerpio ) (Nasdaq: ARPO), a biopharmaceutic
Read more →WHWKAerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected duri
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast
Read more →WHWKTopical Ocular Formulation of Aerpio Pharmaceutical s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypert
Topical Ocular Formulation of Aerpio Pharmaceutical s Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial CINCINNATI January 8, 2020 (BUSINESS WIRE) Aerpi
Read more →WHWKAerpio Reports Third Quarter 2019 Financial Results and Provides Business Update CINCINNATI ( BUSINESS WIRE ) Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that
Aerpio Reports Third Quarter 2019 Financial Results and Provides Business Update CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complica
Read more →WHWKAerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma CINCINNATI
Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma CINCINNATI - October 10, 2019 - (BUSINESS WIRE) - Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical compan
Read more →WHWKAerpio Reports Second Quarter 2019 Financial Results and Provides Business Update CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that a
Aerpio Reports Second Quarter 2019 Financial Results and Provides Business Update CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complic
Read more →WHWKAerpio Reports First Quarter 2019 Financial Results and Provides Business Update On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Q
Aerpio Reports First Quarter 2019 Financial Results and Provides Business Update On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in the Second Quarter of 2019 CINCINNATI (BUSINESS WIRE) Aerpio Pharmace
Read more →WHWKForward looking statements This presentation has been prepared by Aerpio Pharmaceuticals ("we", "us" or, the "Company") and includes forward-looking statements. All statements contained in this presentation other than st
Corporate Presentation April 10, 2019 Forward looking statements This presentation has been prepared by Aerpio Pharmaceuticals ("we", "us" or, the "Company") and includes forward-looking statements. All statements contained in this presentation other than statements of historic
Read more →WHWKAerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 1
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT CINCINNATI Mar. 18, 2019 (BUSINESS
Read more →WHWKAerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Patients with Non-Proliferative Diabet
Aerpio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Top-Line Results from the TIME-2b Clinical Trial Evaluating the Effect of AKB-9778 in Non-Proliferative Diabetic Retinopathy (NPDR) Expected in March 2019 and Webcast Today, March
Read more →WHWKAerpio Reports Third Quarter 2018 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track Conference Call and Webcast Today, November 7 th at 8:30
Aerpio Reports Third Quarter 2018 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track Conference Call and Webcast Today, November 7th at 8:30 a.m. EST CINCINNATI Nov. 7, 2018 (BUSINESS WIRE) Aerpio
Read more →WHWKAerpio Reports Second Quarter 2018 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019 Partnership for AKB-4924 with G
Aerpio Reports Second Quarter 2018 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track; Data in Q2 2019 Partnership for AKB-4924 with Gossamer Bio Will Accelerate Development of the Compound
Read more →WHWKAerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market CINCINNATI Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) ( Aerpio ) today announced that it intends to sell, su
Aerpio Pharmaceuticals Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market CINCINNATI Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) ( Aerpio ) today announced that it intends to sell, subject to market and other conditions, $40 million of its c
Read more →WHWKAerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease CINCINNATI, OH & SAN DIEGO, CA (BUSI
Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924, a First in Class Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease CINCINNATI, OH & SAN DIEGO, CA (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), toda
Read more →WHWKAerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease CINCINNATI (BUSINESS WIRE) Aerpi
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Development for Inflammatory Bowel Disease CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), today announced the initiation of
Read more →WHWKAerpio Reports First Quarter 2018 Financial Results and Provides Company Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI ( BUSINESS WIRE ) Aerpio Pharmaceutical
Aerpio Reports First Quarter 2018 Financial Results and Provides Company Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused
Read more →WHWKAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today,
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call and Webcast Today, March 13th at 8:30 a.m. ET CINCINNATI Aerpio Pharmaceut
Read more →WHWKaerpio pharmaceuticals Forward looking statement This presentation has been prepared by Aerpio Pharmaceuticals ( we , us or, the Company ), solely for information purposes and is for the recipient to familiarize itself w
aerpio pharmaceuticals Forward looking statement This presentation has been prepared by Aerpio Pharmaceuticals ( we , us or, the Company ), solely for information purposes and is for the recipient to familiarize itself with the Company, and the fact that this meeting has taken
Read more →WHWKAerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer CINCINNATI ( BUSINESS WIRE ) Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that M
Read more →WHWKAerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D. as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D. to President and Founder CINCINNATI ( B
Aerpio Pharmaceuticals Announces Appointment of Stephen Hoffman, M.D., Ph.D. as Chief Executive Officer and to the Board of Directors and the Transition of Joseph H. Gardner, Ph.D. to President and Founder CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO),
Read more →WHWKAerpio Pharmaceuticals Commences Trading on the OTCQB Market The Company will trade under the symbol ARPO CINCINNATI ( BUSINESS WIRE ) Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on ad
Aerpio Pharmaceuticals Commences Trading on the The Company will trade under the symbol ARPO CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today t
Read more →WHWKAerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy CINCINNATI-- Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments
Read more →WHWKAerpio Reports First Quarter 2017 Financial Results
Aerpio Reports First Quarter 2017 Financial Results May 16, 2017 08:00 AM Eastern Daylight Time CINCINNATI (BUSINESS WIRE) Aerpio Pharmaceuticals, Inc. ( the Company ), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today report
Read more →WHWKF INANCIAL S TATEMENTS Aerpio Therapeutics, Inc. Years Ended
FINANCIAL STATEMENTS Aerpio Therapeutics, Inc. Years Ended December 31, 2016 and 2015 With Report of Independent Registered Public Accounting Firm Aerpio Therapeutics, Inc. Financial Statements December 31, 2016 and 2015 Report of Independent Registered Public Accounting F
Read more →Competitive Position
How WHWK ranks across every disease it competes inCompetitive Position is a premium feature
See how WHWK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial